Is SeaStar Medical Holding Corporation (NASDAQ:ICU) a buy in 2026?
Hold. SeaStar Medical Holding Corporation is a wait-and-watch at today's price, not a fresh buy.
Real therapy, real FDA approval, real hyperinflammation science, but a $13M shell burning $10M a year needs cash before it needs conviction.
Where ICU is headed
SeaStar sits at an odd intersection. The company owns QUELIMMUNE, an FDA-approved therapy for pediatric acute kidney injury from sepsis, a condition that kills roughly half the kids who get it in ICUs. The device works by pulling the most inflamed immune cells out of circulation during dialysis, which sounds like science fiction until you look at the pivotal data. And yet the market values the whole business at $13 million. That is not a valuation. That is a distressed-security print.
Read the full Compass Direction on ICU
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $3.25).
See the full ICU analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is SeaStar Medical Holding Corporation (NASDAQ:ICU) a buy in 2026?
Hold. SeaStar Medical Holding Corporation is a wait-and-watch at today's price, not a fresh buy. Real therapy, real FDA approval, real hyperinflammation science, but a $13M shell burning $10M a year needs cash before it needs conviction.
What is ICU's Compass Score?
SeaStar Medical Holding Corporation scores 74/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for ICU?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the ICU page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.